Shanghai Medicilon Inc. (SHA:688202)

China · Delayed Price · Currency is CNY

60.30

+4.85 (8.75%)

Mar 27, 2026, 4:00 PM EDT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Drug Discovery and Pharmaceutical Research	495.07M	631.80M	735.24M	612.97M	354.98M
Drug Discovery and Pharmaceutical Research Growth	-21.64%	-14.07%	19.95%	72.68%	40.34%
Preclinical Study	542.21M	733.80M	923.63M	553.53M	310.64M
Preclinical Study Growth	-26.11%	-20.55%	66.86%	78.19%	58.69%
Total	1.04B	1.37B	1.66B	1.17B	665.62M
Total Growth	-24.04%	-17.68%	42.21%	75.25%	48.35%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
China	643.54M	-	-	-	-
Overseas	393.74M	-	-	-	-
Total	1.04B	-	-	-	-

Source: S&P Global Market Intelligence.